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Abstract
Background: Metastatic pulmonary tumors secondary to breast cancer detected either before or after surgery are
predominantly multiple and bilateral. However, in cases detected to have a solitary pulmonary nodule (SPN),
determining whether the lesion represents a primary cancer, metastasis, or a benign pulmonary lesion can be
difficult.
Materials and methods: Between January 2000 and December 2009, we performed breast cancer surgery on
1,226 patients, of which 49 cases (3.9%) were detected to have pulmonary lesions before or after the surgery. In 14
of these patients, video-assisted thoracoscopic surgery was performed to remove a SPN.
Result: Pathological examination of the resected specimens in these 14 cases revealed metastatic pulmonary
tumor in 8 cases, primary lung cancer in 3 cases, and benign disease in 3 cases. While lobectomy was performed
in one of these patients with metastatic pulmonary tumor, the remaining 7 underwent partial resection of the
lung. The primary lung cancer was an adenocarcinoma in all 3 patients, and lobectomy plus mediastinal lymph
node dissection was performed in these patients. The tumor grading based on pathological diagnosis was
T1N0M0, p-Stage 1A in all 3 patients. The prognosis was good in the breast cancer patients in whom the
metastatic lung tumor was a SPN.
Conclusion: Evaluating the immunohistochemical cytokeratin profile and levels of the TTF-1 and GCDFP-15 of the
lesion was useful when distinguishing between pulmonary cancer and metastatic pulmonary tumor. In addition,
some patients exhibited changes in the biological properties of the metastatic tumor, and delete tumor resection
by video-assisted thoracoscopic surgery can be useful for deciding the drug treatment strategy in some cases
Background
Metastasis from breast cancer predominantly involves the
bones, lungs, and liver. Local therapy of metastases
resulting in radical cure is extremely rare, and systemic
pharmacotherapy is usually selected as the basic thera-
peutic approach, with the aim of prolonging life, alleviat-
ing symptoms, and improving the quality of life (QOL) in
breast cancer patients with metastatic tumors. Patients
with metastatic pulmonary lesions often have multiple
lesions and/or pleural effusion. Definitive diagnosis is
achieved by imaging modalities, and pharmacotherapy is
administered. However, in the case of a solitary pulmon-
a r yn o d u l e( S P N ) ,d i s t i n g u i shing between primary lung
cancer, metastatic pulmonary tumor, and a benign
pulmonary lesion can be difficult. In addition, in the case
of metastatic pulmonary tumors, differences in the biolo-
gical properties of the tumor (e.g., estrogen receptor
(ER), progesterone receptor (PgR) and human epidermal
growth factor receptor type 2 (HER2) status, relative to
those of the primary tumor may require revisions of the
therapeutic strategy. We reviewed our experience of such
patients treated by us at our institution.
Materials and methods
From January 2000 through December 2009, we per-
formed breast cancer surgery on 1,226 patients, and iden-
tified pulmonary lesions in 49 of these patients (3.9%),
either before or after the surgery. In 35 of these patients,
we made the diagnosis of metastatic breast cancer on the
basis of detection of multiple lesions and/or pleuritis
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The present review focuses on the remaining 14 patients
who underwent thoracoscopic surgery for removal of a
SPN of indeterminate diagnosis that was located in the
peripheral lung. All the 14 patients were women, with a
mean age of 58.4 years (range, 44-76 years). Three
women were premenopausal, and the remaining 11 were
postmenopausal.
In our breast cancer patients who were asymptomatic,
we conducted periodic checkups for the detection of pul-
monary lesions, including chest computed tomography
(CT), before breast cancer surgery and then annually for
10 years following the surgery. When a SPN of indeter-
minate diagnosis was detected, resection was performed
by video-assisted thoracoscopic surgery (VATS) if the
lesion was a solid mass measuring ≥ 1.0 cm in diameter.
In the case of a nodular lesion or ground-glass opacity
(GGO) measuring < 1.0 cm in diameter, VATS was per-
formed after 3-6 months, if re-examination showed no
tendency towards shrinkage of the tumor. The resected
specimens were subjected to intraoperative rapid patho-
logical diagnosis, and the subsequent operative method
was determined based on the findings. At the case to
have thought that the identification of the nodule was
difficult about, it did a marking under the CT guide
before the operation. We detained a hook wire with the
thread in the nodule. In the case of lesions for which dis-
tinguishing between primary lung cancer and metastatic
breast cancer during surgery was difficult, the therapeutic
strategy was determined based on the final diagnosis
reached by final histopathological examination of the
resected specimens.
Results
1. Histological diagnoses of SPNs
Histopathological examination of the resected SPNs in
the 14 patients showed metastatic pulmonary tumor in 8
patients (57.1%), primary lung cancer in 3 patients
(22.0%), and benign disease in the remaining 3 patients.
While lobectomy was performed in one of these patients
with metastatic pulmonary tumor, the remaining 7
underwent partial resection of the lung. The primary
lung cancer was an adenocarcinoma in all 3 patients, and
lobectomy +mediastinal lymph node dissection was per-
formed in these patients. We enforced immediately
lobectomy and lymohadenectomy in 2 cases which diag-
nosed lung cancer during enforcement of thoracoscopy.
1 case which was not diagnosed lung cancer enforced
lobectomy after some time. The tumor grading based on
pathological diagnosis was T1N0M0, p-Stage 1A in all 3
patients. The benign disease was mycobacteriosis in 2
patients and mycosis in 1 patient. Partial pulmonary
resection were performed in all 3 cases.
2. Tumor size
Tumor diameter in the 8 patients with metastatic pulmon-
ary tumors was < 1.0 cm in 4 patients, 1.0 to 2.0 cm in
3 patients, and > 2.0 cm in 1 patient. The diameter of the
primary lung cancer tumor was < 1.0 cm in 1 patient and
1.0 to 2.0 cm in the remaining 2 patients, the difference
not being significant. In addition, the lesion diameter in
the case of benign lung disease was 1.0 to 2.0 cm in
2 patients and > 2.0 cm in 1 patient.
3. Outcomes of the patients with metastatic breast cancer
(Tables 1, 2)
One of the 8 patients with metastatic pulmonary tumor
showed metastases to multiple organs and died within
15 months after the breast surgery, whereas the remaining
other 7 patients were still alive as of this writing. On the
other hand, the MST (median survival time) in the
patients with pulmonary metastases, including those with
changed biochemical-characteristics of the metastatic lung
tumor (8 cases), those with multiple-metastases, and those
with metastases to other organs, was 37 months. The
prognosis was good in the breast cancer patients in whom
the metastatic lung tumor was a SPN. The biological prop-
erties of the metastatic lesion differed from those of the
primary lesion in 2 patients: ER(1+), PgR(-), HER2(-)
changing to ER(-), PgR(-), HER2(-) in 1 patient, and ER(2
+), PgR(-), HER2(3+) changing to ER(-), PgR(-), HER2(3+)
in the other patient. Treatments for those 2 patients con-
sisted of weekly paclitaxel (PTX) for 1 patient and trastu-
zumab plus weekly PTX for the other.
4. Case report
A 65-year-old Japanese woman had undergone standard
mastectomy 6 years earlier, and had been administered
postoperative chemotherapy on the basis of the biologi-
cal properties of the drug, namely, t2n1, ER(-), and PgR
(-). While the clinical course was being monitored, peri-
odic, thoracic CT examination revealed a pulmonary
mass shadow measuring 1.2 cm in diameter in the right
Table 1 Cases of lung metastasis from breast cancer
Case Age p-TNM Pathology Grade DFI
1 55 T1N0M0 Scirrhous ca. II 9 M
2 68 T1N0M0 Mucinous ca. II 63 M
3 66 T1N0M0 Scirrous ca. II 48 M
4 69 T2N1M0 Invasive micropapillary ca. I 13 M
5 59 T2N0M0 Scirrhous ca. II 37 M
6 61 T2N0M0 Scirrhous ca. II 26 M
7 65 T2N1M0 Solid-tubular ca. II 12 M
8 44 T1N1M0 Scirrhous ca. II 34 M
DFI: disease-free interval; TNM, TNM classification; Grade, nuclear grade; ca.,
carcinoma.
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performed in the previous year. The possibility of pri-
mary lung cancer could not be ruled out based only on
the CT finding, therefore, VATS resection was per-
formed. It was not possible to determine by intraopera-
tive rapid pathological diagnosis whether the lesion
represented a primary lung cancer or a metastatic
tumor, and the surgery was completed. Immunohisto-
chemical staining of the resected specimen showed a
cytokeratin (CK) profile of CK7(+) and CK20(-), charac-
teristic of pulmonary adenocarcinoma, while the tumor
tissue was also positive for thyroid transcription factor
(TTF)-1, a lung cancer marker, and negative for gross
cystic disease fluid protein (GCDFP)-15, a breast cancer
marker. The tumor was thus diagnosed as a primary
lung cancer (Figure 2, 3, 4 and 5). Three weeks later,
right upper lobectomy and mediastinal lymph node
resection were performed. The final diagnosis in the
tumor was moderately differentiated adenocarcinoma, p-
T1N0M0. No adjuvant chemotherapy was administered,
and the patient remains alive with no evidence of recur-
rence, as of this writing.
Discussion
Pulmonary metastases following surgery for breast cancer
are usually detected as multiple pulmonary nodules and/
or pleural carcinomatosis, representing multiple nodules
and/or pleural effusion or lymphatic carcinomatosis
caused by malignant pleuritis. Diagnosis is normally com-
paratively easy. However, in the case of detection of a
SPN on preoperative examination or during postopera-
tive follow-up of breast cancer patients, accurate diagno-
sis can be very difficult. Mery et al. [1] performed
Table 2 Changes in biochemical characteristics lung
metastasis from breast cancer
Case ER PgR HER2 ER* PgR* HER2* Therapy Result
1 - - - - - - - 76A
2 - - 1+ - - 1+ - 48A
3 1+ - - - - - Chemo 35A
4 2+ 1+ - 2+ 1+ - Chemo 35D
5 2+ 3+ 3+ 2+ 1+ 3+ Endocrine 34A
6 2+ - 3+ - - 3+ Chemo+Tr 26A
7 - - 3+ - - 3+ Chemo+Tr 25A
8 1+ 3+ 3+ 2+ 2+ 2+ Endocrine+Tr 18A
ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal
growth factor receptor type 2; ER*, ER after resection; PgR*, PgR after
resection; HER2*, HER2 after resection; Chemo, chemotherapy; Endocrine,
endocrine therapy; Tr, trastuzumab; A, alive; D,death
Figure 1 CT image. A nodular shadow, 10 mm in diameter, is seen
in the right S10 region.
Figure 2 CK-7-positive tumor. CK-7-positive tumor of
immunohistochemical staining (×100) cells.
Figure 3 CK-20-negative tumor cells. CK-20-negative tumor cells
of immunohistochemical staining (×100) cells.
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patients with antecedent cancers. They reported that
approximately 80% of the patients had malignant disease,
with primary pulmonary carcinoma in 41% and meta-
static pulmonary tumors in 38% of the patients. Quint et
al. [2] studied 161 patients and found that 50.3% had pri-
mary pulmonary carcinoma and 31.1% had metastatic
pulmonary tumor. In addition, Rena et al. [3] reported
that, among 79 patients who had undergone radical sur-
gery for breast cancer, 48.1% developed primary pulmon-
ary carcinoma and 30.4% developed metastatic pulmonary
tumors. The corresponding incidences at our institution
were 22.1% and 57.1%, respectively. Our combined inci-
dences of approximately 80% for primary and metastatic
malignant pulmonary tumors is consistent with the inci-
dences reported by others, however, the percentage of
metastatic pulmonary tumors in our series was higher.
This can be attributed to the fact that our base analytical
population comprised patients who had undergone radical
surgery for breast cancer at our institution and did not
include patients who had been referred to us after radical
surgery performed at another institution. In any case, in
the event of detection of a SPN, the possibility of primary
pulmonary carcinoma should be borne in mind.
The size of the pulmonary tumor was ≤ 2.0 cm in all
but 2 of our patients. This can be ascribed to the fact
that the periodic CT examinations facilitated early detec-
tion of tumors in almost all patients. Burden et al.
reported that 41.7% of tumors measuring < 1.0 cm in dia-
meter were malignant, demonstrating that malignancy is
not unusual even in tumors with such a small diameter
[4]. Recent years have seen increased application of
VATS, allowing less invasive pulmonary resection as
compared to conventional open-chest surgery. VATS is
now performed at many institutions, and its usefulness
has been documented [5,6].
We perform intraoperative rapid pathological diagnosis,
but differentiating between pulmonary adenocarcinoma
and metastatic pulmonary tumor can be difficult. Exami-
nation of permanent specimens is therefore sometimes
necessary for a definitive diagnosis, on immunohistochem-
ical staining, pulmonary and thyroid adenocarcinomas
characteristically shows that TTF-1 [7]. In addition, stain-
ing for the glycoprotein GCDFP-15, a marker of breast
cancer, and for CK7 and CK20 is also considered to be
useful for making a definitive diagnosis [8,9]. In the case
reported above, we were unable to reach a definitive diag-
nosis during surgery. However, we obtained a definitive
diagnosis of pulmonary adenocarcinoma with an immu-
nostaining profile of CK7(+), CK20(-), GCDFP-15(-)
and TTF-1(+) by examination of permanent resected
specimens.
Another important point that must be taken into con-
sideration in the case of metastatic pulmonary tumors in
breast cancer patients is the possibility of changes in the
original molecular biological profile of the tumor. In two
of our patients, the primary breast cancers was ER-posi-
tive, whereas the metastatic tumor was negative for this
marker. This phenomenon is sometimes seen even in
patients with local recurrence or recurrence in other
organs. With regard to treatments administered following
lung surgery, tailoring treatment to the biological charac-
teristics of the pulmonary metastatic tumor is imperative.
We administered anticancer drugs as postoperative treat-
ment. Based on our present experience, when pharma-
cotherapy exerts inadequate efficacy in a patient with
multiple lung metastases from breast cancer, the possibi-
lity of changes in the molecular biological properties of
the metastatic tumor should be considered. If the patient
is in good overall health, consideration should be given to
performing tumor biopsy via VATS.
Figure 4 TTF-1-positive tumor cells. TTF-1-positive tumor cells of
immunohistochemical staining (×100) cells.
Figure 5 GCDFP-5-negative tumor cells. GCDFP-5-negative tumor
cells of immunohistochemical staining (×100) cells.
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In the case of detection of a SPN, determining whether the
lesion represents primary cancer, metastasis or a benign
pulmonary lesion can be difficult. Evaluating the immuno-
histochemical cytokeratin profile of the lesion in terms of
CK7 and CK20 was useful when distinguishing between
pulmonary adenocarcinoma and metastatic pulmonary
tumor was difficult, along with levels of the lung cancer
marker TTF-1 and the breast cancer marker GCDFP-15.
In addition, some patients exhibited changes in the biolo-
gical properties of the metastatic tumor, and delete tumor
resection by video-assisted thoracoscopic surgery can be
useful for deciding the drug treatment strategy in some
cases
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